S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
NASDAQ:MEIP

MEI Pharma - MEIP Stock Forecast, Price & News

$0.23
-0.01 (-4.22%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.22
$0.24
50-Day Range
$0.21
$0.35
52-Week Range
$0.20
$0.70
Volume
342,018 shs
Average Volume
1.65 million shs
Market Capitalization
$30.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

MEI Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,220.4% Upside
$3.00 Price Target
Short Interest
Bearish
3.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.22mentions of MEI Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$18,745 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.27) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

404th out of 1,002 stocks

Pharmaceutical Preparations Industry

186th out of 488 stocks


MEIP stock logo

About MEI Pharma (NASDAQ:MEIP) Stock

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Stock News Headlines

MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
MEI Pharma winst en omzet hoger dan voorspeld
MEI Pharma Initiates Strategic Realignment
MEI Pharma First Quarter 2023 Earnings: Beats Expectations
MEI Pharma, Inc. (MEIP)
MEI Pharma Announces Changes to Board of Directors
See More Headlines
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Company Calendar

Last Earnings
2/09/2023
Today
3/29/2023
Next Earnings (Estimated)
5/22/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,220.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-54,450,000.00
Pretax Margin
-49.80%

Debt

Sales & Book Value

Annual Sales
$62.57 million
Book Value
$0.39 per share

Miscellaneous

Free Float
125,052,000
Market Cap
$30.28 million
Optionable
Optionable
Beta
1.03

Key Executives

  • Daniel P. Gold
    President, Chief Executive Officer & Director
  • David M. Urso
    Chief Operating Officer & General Counsel
  • Brian G. Drazba
    Chief Financial Officer & Secretary
  • Richard G. Ghalie
    Chief Medical Officer
  • Benjamin Cadieux
    Vice President-Medical Affairs













MEIP Stock - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings
or view top-rated stocks.

What is MEI Pharma's stock price forecast for 2023?

5 Wall Street analysts have issued 12-month target prices for MEI Pharma's shares. Their MEIP share price forecasts range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,220.4% from the stock's current price.
View analysts price targets for MEIP
or view top-rated stocks among Wall Street analysts.

How have MEIP shares performed in 2023?

MEI Pharma's stock was trading at $0.2436 at the start of the year. Since then, MEIP stock has decreased by 6.7% and is now trading at $0.2272.
View the best growth stocks for 2023 here
.

Are investors shorting MEI Pharma?

MEI Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 5,270,000 shares, an increase of 20.9% from the February 28th total of 4,360,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is currently 4.7 days.
View MEI Pharma's Short Interest
.

When is MEI Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023.
View our MEIP earnings forecast
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings results on Thursday, February, 9th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.24. The firm earned $32.74 million during the quarter, compared to analysts' expectations of $9.69 million. MEI Pharma had a negative net margin of 49.80% and a negative trailing twelve-month return on equity of 88.33%.

What other stocks do shareholders of MEI Pharma own?
What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.00%), Millennium Management LLC (0.26%), Wells Fargo & Company MN (0.20%), Morgan Stanley (0.14%), Two Sigma Investments LP (0.14%) and UBS Group AG (0.10%). Insiders that own company stock include Charles V Baltic III and Frederick W Driscoll.
View institutional ownership trends
.

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $0.23.

How much money does MEI Pharma make?

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $30.28 million and generates $62.57 million in revenue each year. The company earns $-54,450,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.

This page (NASDAQ:MEIP) was last updated on 3/29/2023 by MarketBeat.com Staff